Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Clinical trial NCT05976893 · UNKNOWN

Trial details

NCT number: NCT05976893
Sponsor: Xiang Xie
Status: UNKNOWN
Phase: Phase 4
Study type: INTERVENTIONAL

ASCVD Atherosclerotic Cardiovascular Disease Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Cancer

Start date: 2023-08-01
Primary completion: 2025-12-31
Enrollment: 620

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.